- Open Access
The new Rapid-i carrier is an effective system for human embryo vitrification at both the blastocyst and cleavage stage
© Desai et al.; licensee BioMed Central Ltd. 2013
Received: 1 March 2013
Accepted: 2 May 2013
Published: 15 May 2013
The Rapid-i is a new FDA cleared closed carrier for embryo vitrification. The cooling rate of - 1220°C/min is far lower than that reported with open vitrification systems such as the cryoloop (−15,000°C/min). Little published data is currently available on this device. This study presents our initial clinical data, as well as live birth outcomes, with the Rapid-i. The efficacy of this device for the cryopreservation of cleavage, as well as blastocyst stage human embryos is also analyzed. We further compare outcomes to those achieved with the cryoloop, an “open” vitrification system routinely used in our laboratory.
Human embryos were vitrified at either the 8–10 cell stage or else the blastocyst stage. The vitrification protocol was: 7.5% DMSO/7.5% ethylene glycol (EG) (2–3 min) followed by incubation in 15% DMSO /15% EG (45 sec) before loading on the vitrification carrier. Cryoprotectant was removed during warming by sequential washes in 0.25 M and 0.125 M sucrose in culture medium. Clinical outcome data for frozen cycles between January 2011 and August 2012 were stratified according to carrier and cell stage. The student t-test and chi square test were used to compare results. P value of < 0.05 was considered significant.
A total of 486 vitrified-warmed embryos were assessed and 92% of them were transferred. The clinical pregnancy rate (CPR) and implantation rate (IR) with Rapid-i vitrified blastocysts were 59% and 49%, versus 47% and 37%, respectively for cleavage stage embryos. This was not statistically different from results with the cryoloop vitrified blastocysts (CPR 46%, IR 38%) nor the cleavage stage vitrified embryos (CPR 49%, IR 35%). To date, there have been 31 deliveries of 34 healthy infants from Rapid-i vitrified embryos, with another 12 pregnancies still on-going.
The Rapid-i offers an excellent alternative to existing open vitrification devices for embryo cryopreservation at the 8–10 cell stage as well as the blastocyst stage. Use of this type of “closed” sealed system that prevents direct contact between the embryos and liquid nitrogen reduces the potential risk of sample cross-contamination or infection. These preliminary data and live birth outcomes have paved the way toward transitioning to a closed vitrification system in our own IVF program.
Vitrification is rapidly replacing slow cryopreservation as the method of choice for embryo freezing in clinics world-wide. Increasing evidence from published outcomes with both techniques suggest that vitrification may in fact be superior to slow cooling [1–7].
In contrast to slow cryopreservation methods, which use cooling rates of - 0.3°C per minute, vitrification uses rapid cooling rates to preserve the embryo instantaneously in a “glass-like state”. Vitrification requires high concentrations of cryoprotectant combined with high cooling rates to transition from a fluid to solid state without a phase change thus avoiding intra or extracellular ice crystallization . A practical limitation to establishing successful vitrification protocols has been the achievement of sufficiently high cooling rates in conventional freezing vessels [7, 9, 10]. Developing vessels to sequester the cell in miniscule fluid volumes, of a microliter or less, has been one approach to increasing cooling rates.
Human embryos have been cryopreserved with a variety of different vitrification devices or carriers that can be classified as either “open” or “closed”. “Open” vitrification devices allow direct contact of the embryos with liquid nitrogen. Much of the early work establishing the efficacy of vitrification, and documenting the first live births, were performed using open carriers like the cryoloop [11–13], EM grids , Cryotop  and open pulled straws [16–19]. Despite successful use of “open” carriers for embryo vitrification, direct contact between the embryo and liquid nitrogen may not be desirable as there is a potential risk of cross-contamination between specimens or inadvertent exposure to contaminants present in the tank [20–22]. The use of “closed” vitrification carriers circumvents these risks. Examples of closed carrier systems include; cryotips (Irvine Scientific, CA, USA), high security vitrification straw (HSV) (Cryo BioSystem, Paris, France), VitriSafe (VitriMed, Austria) and Cryopette (Origio, Denmark). Initial concerns that the lower cooling rates with closed sealed vitrification systems may compromise pregnancy outcomes have been dispelled by recent publications using commercially marketed “closed” vitrification carriers [2, 23–26].
The Rapid-i is a new “closed“ vitrification device, recently received FDA clearance for embryo vitrification. The cooling rate of −1220°C/min is far lower than that reported with other vitrification systems [26, 27]. Little published data is currently available on this new carrier [28–30]. The present work summarizes our initial clinical data, as well as live birth outcomes, with the Rapid-i. The efficacy of this device for the cryopreservation of early, as well as late stage, human embryos is also analyzed. We further compare outcomes to those achieved in our laboratory with an “open” vitrification system, namely the cryoloop, with its high cooling rate of −15,000°C /min.
Embryo vitrification using the Rapid- i carrier was introduced into our clinical practice in January 2011 for cryopreservation of day 3 cleavage stage embryos as well as blastocysts. Prior to this, embryo vitrification was performed using the cryoloop.
This study examines outcomes from patients ≤40 years of age returning to the Cleveland Clinic Fertility Center for a frozen embryo transfer (FET) cycle between January 2011 and August 2012. During this time period, 95 couples returned for an FET cycle with embryos vitrified with the new Rapid-i carrier. Another 161 couples had an FET cycle with embryos vitrified prior to 2011 using the cryoloop carrier. Outcome data was retrospectively analyzed from our IVF laboratory database registry in accordance with the ethical policy and guidelines set forth by the Cleveland Clinic’s Institutional Review Board.
Ovarian stimulation and IVF
Women were treated with either a GnRH-agonist (gonadotropin releasing hormone) or a GnRH-antagonist to suppress ovulation until follicle maturity was attained. Ovarian stimulation was initiated using daily injections of follicle stimulating hormone (FSH) at starting doses of 225 IU per day or adjusted based on serum anti-mullerian hormone levels, antral follicle counts and the response to previous stimulations. Subsequent doses were adjusted according to transvaginal ultrasonograms and serum estradiol levels. Final follicular maturation was triggered with human chorionic gonadotrophin (hCG) when at least two lead follicles measured 18 mm in mean diameter. Oocytes were collected 36 hours later by transvaginal needle aspiration of follicles under ultrasound guidance.
Mature oocytes were inseminated by intracytoplasmic sperm injection 2–4 hours after retrieval. Intermediate and immature oocytes underwent conventional IVF insemination. Oocytes were examined 16–18 hours after insemination for the presence of two pronuclei. Zygotes were individually cultured in 20 μl drops of Global medium (LifeGlobal, Guilford, CT) supplemented with 10% Synthetic Protein Supplement (SPS; Cooper Surgical; Trumbull, CT) under an oil overlay. All culture was performed at 37°C with 6% CO2 in air. Fresh embryo transfers were performed on day 5 for patients with 8 or more good quality embryos and on day 3 for all other patients.
Embryos were observed and graded daily. Cleavage stage embryos were assessed for cell stage, percent fragmentation, multinucleation, blastomere symmetry and degree of cell:cell adherence. Blastocyst grade was assigned based on day of blastocyst formation, blastocyst maturity, inner cell mass development, trophectoderm appearance and degree of necrosis after warming using a previously described scoring system [31, 32]. Blastocoel volume and expansion were used to classify blastocysts as: A = early blastocyst, cavity just starting to form; B = early blastocyst, cavity less than half the volume of embryo; C = expanded with cavity greater than half embryo volume; D = fully expanded; and E = hatching. The inner cell mass was graded as: 0- absent or not yet visible; 1- sparse, few cells; and 2- well defined, discrete cell mass. Trophectoderm of the blastocyst was assessed based on overall cell number and organization: 1- low cell number, stretched appearance; 2- well organized cohesive cell layer; and 3- extremely high cell number but well organized.
Embryo cryopreservation was carried out on day 3 at the cleavage stage or on days 5/6 at the blastocyst stage. For day 3 cryopreservation, embryos needed to be between 8–10 cells with even blastomeres and <20% fragmentation. Embryos not meeting these criteria were kept in extended culture and vitrified if they reached the blastocyst stage. Patients having a fresh blastocyst transfer had their supernumerary blastocysts (grades B-E), which displayed an inner cell mass, cryopreserved on day 5. The remaining embryos were given an extra day to develop in culture. In a few patients, morula and early blastocysts without a clearly visible ICM were cryopreserved if nothing else was available for cryobanking by day 6.
A two-step vitrification protocol was used for both cleavage and blastocyst stage embryos . This technique uses dimethylsulfoxide (DMSO), ethylene glycol (EG) and sucrose as the cryoprotectant agents (CPA). Embryos were loaded either singly or in pairs on to the carrier and vitrified. All vitrification solutions were prepared in-house. Vitrification Solution #1 (VS1) consisted of 7.5% DMSO and 7.5% EG in Global medium with 20% SPS. Vitrification Solution #2 (VS2) contained 15% DMSO, 15% EG, 10 mg/ml Ficoll-70 and 0.65 M sucrose. All incubations steps were performed at 37°C. Embryos were rinsed and held in VS1 for 2 min (3 min for blastocysts). Embryos were then quickly moved through three drops of VS2, holding for 15 sec in each drop, before loading on the vitrification carrier in use at the time.
The technique for cryoloop loading involved first preparing a film of cryoprotectant on the loop by dipping in VS2. The embryos were then quickly loaded on to the film using a micropipette (Figure 1). Immediately after loading, the cryoloop with embryos was immersed in a cryovial containing liquid nitrogen. The magnetic cap was tightened using a metal wand and the vial was then moved to the liquid nitrogen storage tank.
Artificial collapse of blastocysts
Warming of embryos and assessment of survival
Cryoprotectant was removed by two sequential washes in warming solutions containing decreasing concentrations of sucrose (0.25 M and 0.125 M) in Global medium with 20% SPS. All steps were performed at 37°C with pre-equilibrated solutions. Warming solutions (0.5 ml) were placed in the center well of two organ culture dishes. A third wash dish was set up with culture medium for rinsing.
The Rapid-i straw was placed in a small dewar containing liquid nitrogen. The straw was cut and the inner Rapid-i stick with the embryos was firmly grasped, while still partially submerged in liquid nitrogen. The Rapid-i stick was then quickly pulled free of the straw and immersed in the first warming solution (0.25 M sucrose) and swirled to unload the embryos. The dish was then carefully examined under the dissecting scope and the embryos located. After two minutes, the embryos were moved to the second warming solution (0.125 M sucrose). After three minutes, the embryos were placed in the wash dish and incubated for an additional five minutes. Essentially the same procedure was used for warming embryos vitrified on the cryoloop. The embryos were unloaded by immersing the cryoloop directly in the first warming solution.
After the warming steps were completed, cleavage as well as blastocyst stage embryos underwent assisted hatching using a 1.48 μm diode laser. Two to three laser pulses were delivered to open the zona. The embryos were then transferred to a culture dish and examined under an inverted microscope at 400× magnification to assess for signs of cryoinjury and blastomere damage. Cleavage stage embryos were considered to have “survived” if at least half of the blastomeres were intact. Following warming, cleavage embryos were cultured for 48 hours to confirm continued developmental competency.
Cryosurvival of vitrified- warmed blastocysts, was determined on the basis of morphology immediately after warming. Blastocysts with dark, granular appearing cells and large areas of degeneration were identified as “non-surviving”. Warmed blastocysts were incubated for 2 hours and re-examined before transfer. Blastocoel expansion, trophectoderm organization and inner cell mass presence and cohesiveness were once again scored. A photographic record was kept of embryo morphology immediately after warming and just before transfer. After assessment of morphology, the embryos were moved to an organ culture dish containing Embryo Glue (VitroLife; Englewood, Colorado) in preparation for the transfer procedure.
Embryo transfer and pregnancy assessment
Patients were prepared for frozen embryo transfer using endometrial priming with daily oral estradiol (6 mg) beginning on cycle day 1 and intramuscular (IM) progesterone (50–100 mg) starting on day 13. The endometrial lining was monitored for thickness and trilaminar appearance before starting progesterone therapy. Cycles were cancelled if the endometrial thickness was <7 mm. Transfer of vitrified-warmed blastocysts was performed after 6 days of progesterone treatment. Cleavage stage vitrified embryos were replaced after 5 days of progesterone. Embryo transfer was performed under transabdominal ultrasound guidance using a Wallace Sure-View catheter. Progesterone was continued for luteal support. Serum hCG levels were measured 15 days after transfer to detect pregnancy. A clinical pregnancy was confirmed by visualization of an intrauterine gestational sac with fetal heart activity on ultrasound 4 weeks after the embryo transfer. The implantation rate (IR) was calculated by dividing the number of gestational sacs by the number of embryos transferred. Ongoing pregnancy was defined as pregnancies continuing past 12 weeks gestation.
Outcome parameters and data analysis
Outcome measures monitored were embryo survival (>50% intact), morphology at transfer, clinical pregnancy rate per transfer (CPR) and implantation rate. Clinical outcome data for frozen cycles between January 2011 and August 2012 were stratified according to carrier and cell stage. For data analysis, blastocyst FET cycles were further categorized according to the morphology of the transferred embryos post-warming. Embryos vitrified at the cleavage stage were monitored for resumption of mitosis, genomic activation and blastulation during the 48 hour culture interval before transfer. The student t-test, chi square test and Fischer’s exact test were used as appropriate to compare outcome parameters. Data is expressed as mean ± SD (standard deviation). P values of <0.05 were considered to be statistically significant. Statistical analysis was performed using the software Stats Direct (Cheshire, UK).
Comparison of vitrification outcomes for day 3 cleavage and blastocyst stage embryos using different carriers
Stage at Vitrification
33.6 ± 3.3
34.1 ± 3.7
34.2 ± 3.8
34. ± 3.2
No vitrification-warming cycles
No. vitrified embryos warmed
No. intact embryos on warming (%)
Mean no. embryos thawed
2.1 ± 0.7
2.0 ± 10.4
1.8 ± 0.7
1.8 ± 0.7
No. embryos surviving and transferred
Mean no. embryos transferred
2.0 ± 0.5
1.9 ± 0.4
1.7 ± 0.5
1.7 ± 0.5
Implantation rate (%)
Clinical pregnancy rate (%)
Multiple pregnancy rate (%)
Miscarriage rate (%)
Outcomes with blastocyst vitrification on the Rapid-i appeared somewhat higher than those achieved with cryoloop but the differences did not reach statistical significance. The clinical pregnancy rates were 59% vs. 46%, respectively; p = 0.199 and the implantation rates were 49% vs. 38 %; p = 0.128. The mean number of embryos warmed was 1.8 for both treatment groups. The survival rate of vitrified blastocysts was 97% with the Rapid-i versus 91% with the cryoloop (p = 0.07). Transfer of Rapid-i vitrified blastocysts has to date resulted in the birth of 18 healthy babies (9 boys and 9 girls), with 9 pregnancies still-ongoing and 5 miscarriages. Once again, the on-going pregnancy rate did not differ from that observed with cryoloop vitrification (49% vs. 39%).
The Rapid-i is a brand new vitrification carrier and this is one of the first clinical studies documenting its efficacy with human embryos at both early and late developmental stages. This is also the first report on live birth rates with the Rapid-i. The impact of the lower cooling rate during vitrification was of particular concern to us, especially as it relates to different embryonic stages and blastomere cell size. Our data however clearly indicate that the Rapid-i carrier can be effectively applied to both early cleavage as well as blastocyst stage embryos.
The basic premise underlying the design of new vitrificaton systems and carriers has, to date, been focused on achieving high cooling rates. As pointed out by Seki and Mazur , cryoinjury may in fact be more related to recrystallization during warming rather than the failure to vitrify. In that study, the authors examined the relationship between cooling versus warming rates and vitrification results with mouse oocytes. They concluded that a warming rate of at least 3000°C/min was necessary to achieve 80% survival. Moreover, their data indicated that if the warming was quick enough, a cooling rate of as low as −200°C/min should be adequate for successful vitrification.
Our present data with human embryos certainly concurs with the relative importance of the warming over the cooling rate. The warming temperature of 7700°C/min with the Rapid-i was clearly sufficient to give outcomes comparable to an open system like the cryoloop, despite a 15-fold lower cooling rate of −1220°C/min. The 59% CPR and 49% implantation rate achieved with Rapid-i blastocyst vitrification closely parallels pregnancy outcomes from fresh single embryo transfer of blastocysts at our IVF center (unpublished results). We also found that the lower cooling rate with the Rapid-i was not a deterrent to successful vitrification of day 3 cleavage embryos despite the larger size of the individual blastomeres. According to the SART (Society for Assisted Reproductive Technology) registry’s 2011 national summary data, young patients under 35 having a fresh transfer had a 36% implantation rate. It was reassuring that we were able to achieve this same implantation rate with Rapid-i vitrified 8-cell embryos.
Concerns have been raised regarding the safety of open vitrification carriers for the cryopreservation of reproductive cells [2, 20–22, 35]. Although, there have been no reported incidents of human reproductive tissue contamination during storage in liquid nitrogen tanks to date, there has been a movement toward the use of “closed” sealed systems for human gamete/embryo cryopreservation. The long-standing argument for use of open systems has been that the benefit of higher cooling rates and ease of embryo loading/recovery far outweigh the theoretical risks of using such and open system. This former objection is rapidly becoming obsolete with accumulating pregnancy outcome data from closed vitrification carriers . The current data set provides further evidence to suggest that a closed vitrification carrier can be used effectively for embryos at both early and late stages. Despite the far lower cooling and warming rates with the Rapid-i (−1220°C/min, +7700°C/min) compared to the HSV straw (−2900°C/min, +25,000°C/min) [26, 27], clinical outcomes more than matched those with the HSV (CPR 45%, IR 31%) . Transitioning to the Rapid-i closed carrier was aided by its clever design. Its resemblance to the cryoloop as far as embryo loading and recovery made it technically easy to use.
It should be noted that with cryopreservation at the blastocyst stage, it was important to critically assess the degree of expansion and alter the vitrification protocol accordingly. Blastocyst collapse was integral to successful vitrification of expanded blastocysts. Cell death and DNA damage is lower if the size of the blastocoelic cavity is reduced prior to vitrification . Vanderzwalmen and colleagues first described the benefit of blastocoel shrinkage to improve cryosurvival . A variety of methods have been applied to reduce blastocoelic volume prior to vitrification leading to improvements in post-warming survival and ultimately, clinical outcomes [14, 15, 18, 37, 38]. Mukaida and colleagues reported an implantation rate of 47% with mechanically or laser collapsed blastocysts vitrified on cryoloops . We had a similarly high 49% implantation rate with mechanically collapsed blastocysts cryopreserved using the the Rapid-i closed vitrification system. In contrast, Hashimoto et al. vitrified blastocysts on the Rapid-i without collapsing and reported clinical outcomes similar to our own . It is likely that the specific vitrification protocol in combination with the type of carrier and the morphology of the blastocyst being cryopreserved may dictate whether or not collapsing is necessary.
In summary, the Rapid-i offers an excellent alternative to existing open vitrification devices for embryo cryopreservation at the 8–10 cell stage as well as at the blastocyst stage. Use of this type of “closed” system that prevents direct contact between the embryos and liquid nitrogen reduces the potential risk of sample cross-contamination or infection. These preliminary data and live birth outcomes have paved the way toward transitioning to a closed vitrification system in our own IVF program. The ease of embryo loading and unloading played an important role in the selection and acceptance of this particular device as opposed to other commercially available closed vitrification devices. Additional data from other centers are needed to further corroborate these findings.
Special thanks to the dedicated and talented embryologists at the Cleveland Clinic Fertility Center, Julia, Melanie, Alyssa and Mary for their excellent work with embryo vitrification.
- Stehlik E, Stehlik J, Katayama KP, Kuwayama M, Jambor V, Brohammer R, Kato O: Vitrification demonstrates significant improvement versus slow freezing of human blastocysts. Reprod Biomed Online. 2005, 11: 53-57. 10.1016/S1472-6483(10)61298-9.View ArticlePubMedGoogle Scholar
- Kuwayama M, Vajta G, Ieda S, Kato O: Comparison of open and closed methods for vitrification of human embryos and the elimination of potential contamination. Reprod Biomed Online. 2005, 11: 608-614. 10.1016/S1472-6483(10)61169-8.View ArticlePubMedGoogle Scholar
- AbdelHafez FF, Desai N, Abou-Setta AM, Falcone T, Goldfarb J: Slow freezing, vitrification and ultra-rapid freezing of human embryos: a systematic review and meta-analysis. Reprod Biomed Online. 2010, 20: 209-222. 10.1016/j.rbmo.2009.11.013.View ArticlePubMedGoogle Scholar
- Loutradi KE, Kolibianakis EM, Venetis CA, Papanikolaou EG, Pados G, Bontis I, Tarlatzis BC: Cryopreservation of human embryos by vitrification or slow freezing: a systematic review and meta-analysis. Fertil Steril. 2008, 90: 186-193. 10.1016/j.fertnstert.2007.06.010.View ArticlePubMedGoogle Scholar
- Kolibianakis EM, Venetis CA, Tarlatzis BC: Cryopreservation of human embryos by vitrification or slow freezing: which one is better?. Curr Opin Obstet Gynecol. 2009, 21: 270-274. 10.1097/GCO.0b013e3283297dd6.View ArticlePubMedGoogle Scholar
- Desai N, AbdelHafez F: Human Embryo Cryopreservation. Infertility Diagnosis, Managment and IVF. Edited by: Dubey A. 2012, Jaypee Medical Pub, 499-[Dubey A (Series Editor)Google Scholar
- Vajta G, Nagy ZP: Are programmable freezers still needed in the embryo laboratory? Review on vitrification. Reprod Biomed Online. 2006, 12: 779-796. 10.1016/S1472-6483(10)61091-7.View ArticlePubMedGoogle Scholar
- Rall WF, Fahy GM: Ice-free cryopreservation of mouse embryos at −196 degrees C by vitrification. Nature. 1985, 313: 573-575. 10.1038/313573a0.View ArticlePubMedGoogle Scholar
- Liebermann J, Tucker MJ: Effect of carrier system on the yield of human oocytes and embryos as assessed by survival and developmental potential after vitrification. Reproduction. 2002, 124: 483-489. 10.1530/rep.0.1240483.View ArticlePubMedGoogle Scholar
- Mazur P: Equilibrium, quasi-equilibrium, and nonequilibrium freezing of mammalian embryos. Cell Biophys. 1990, 17: 53-92.View ArticlePubMedGoogle Scholar
- Lane M, Bavister BD, Lyons EA, Forest KT: Containerless vitrification of mammalian oocytes and embryos. Nat Biotechnol. 1999, 17: 1234-1236. 10.1038/70795.View ArticlePubMedGoogle Scholar
- Lane M, Schoolcraft WB, Gardner DK: Vitrification of mouse and human blastocysts using a novel cryoloop container-less technique. Fertil Steril. 1999, 72: 1073-1078. 10.1016/S0015-0282(99)00418-5.View ArticlePubMedGoogle Scholar
- Mukaida T, Nakamura S, Tomiyama T, Wada S, Kasai M, Takahashi K: Successful birth after transfer of vitrified human blastocysts with use of a cryoloop containerless technique. Fertil Steril. 2001, 76: 618-620. 10.1016/S0015-0282(01)01968-9.View ArticlePubMedGoogle Scholar
- Son WY, Yoon SH, Yoon HJ, Lee SM, Lim JH: Pregnancy outcome following transfer of human blastocysts vitrified on electron microscopy grids after induced collapse of the blastocoele. Hum Reprod. 2003, 18: 137-139. 10.1093/humrep/deg029.View ArticlePubMedGoogle Scholar
- Hiraoka K, Hiraoka K, Kinutani M, Kinutani K: Blastocoele collapse by micropipetting prior to vitrification gives excellent survival and pregnancy outcomes for human day 5 and 6 expanded blastocysts. Hum Reprod. 2004, 19: 2884-2888. 10.1093/humrep/deh504.View ArticlePubMedGoogle Scholar
- El-Danasouri I, Selman H: Successful pregnancies and deliveries after a simple vitrification protocol for day 3 human embryos. Fertil Steril. 2001, 76: 400-402. 10.1016/S0015-0282(01)01907-0.View ArticlePubMedGoogle Scholar
- Vanderzwalmen P, Bertin G, Debauche C, Standaert V, Bollen N, van Roosendaal E, Vandervorst M, Schoysman R, Zech N: Vitrification of human blastocysts with the Hemi-Straw carrier: application of assisted hatching after thawing. Hum Reprod. 2003, 18: 1504-1511. 10.1093/humrep/deg298.View ArticlePubMedGoogle Scholar
- Vanderzwalmen P, Bertin G, Debauche C, Standaert V, van Roosendaal E, Vandervorst M, Bollen N, Zech H, Mukaida T, Takahashi K, Schoysman R: Births after vitrification at morula and blastocyst stages: effect of artificial reduction of the blastocoelic cavity before vitrification. Hum Reprod. 2002, 17: 744-751. 10.1093/humrep/17.3.744.View ArticlePubMedGoogle Scholar
- Vanderzwalmen P, Bertin G, Debauche V: In vitro survival of metaphase II oocytes (MII) and blastocysts after vitrification in an hemi-straw (HS) system. Fertil Steril. 2000, 74: S215-S216.View ArticleGoogle Scholar
- Bielanski A, Bergeron H, Lau PC, Devenish J: Microbial contamination of embryos and semen during long term banking in liquid nitrogen. Cryobiology. 2003, 46: 146-152. 10.1016/S0011-2240(03)00020-8.View ArticlePubMedGoogle Scholar
- Bielanski A, Nadin-Davis S, Sapp T, Lutze-Wallace C: Viral contamination of embryos cryopreserved in liquid nitrogen. Cryobiology. 2000, 40: 110-116. 10.1006/cryo.1999.2227.View ArticlePubMedGoogle Scholar
- Bielanski A, Vajta G: Risk of contamination of germplasm during cryopreservation and cryobanking in IVF units. Hum Reprod. 2009, 24: 2457-2467. 10.1093/humrep/dep117.View ArticlePubMedGoogle Scholar
- Liebermann J: Vitrification of human blastocysts: an update. Reprod Biomed Online. 2009, 19 (Suppl 4): 4328-PubMedGoogle Scholar
- Wilding MG, Capobianco C, Montanaro N, Kabili G, Di Matteo L, Fusco E, Dale B: Human cleavage-stage embryo vitrification is comparable to slow-rate cryopreservation in cycles of assisted reproduction. J Assist Reprod Genet. 2010, 27: 549-554. 10.1007/s10815-010-9452-1.PubMed CentralView ArticlePubMedGoogle Scholar
- Vanderzwalmen P, Ectors F, Grobet L, Prapas Y, Panagiotidis Y, Vanderzwalmen S, Stecher A, Frias P, Liebermann J, Zech NH: Aseptic vitrification of blastocysts from infertile patients, egg donors and after IVM. Reprod Biomed Online. 2009, 19: 700-707. 10.1016/j.rbmo.2009.09.011.View ArticlePubMedGoogle Scholar
- CryoBio: Pre-market notification K092398 HSV Straw. 2010Google Scholar
- Tarakanov Y, Johansson B, Lehmann H, Appell SP: Numerical Simulations Demonstrate Safe Vitrification and Warming of Embryos Using the Rapid-i Device. Proceedingsof the COMSOL Conference; Milan, Italy. 2009Google Scholar
- Desai N, Goldberg J, Austin C, Falcone T: The new Rapid i carrier is an effective closed system for human embryo vitrification at both the blastocyst and cleavage stage. Hum Reprod. 2012, 27: Supplement2,ii59-60,O-154Google Scholar
- Hashimoto S, Amo A, Hama S, Ohsumi K, Nakaoka Y, Morimoto Y: A closed system supports the developmental competence of human embryos after vitrification : Closed vitrification of human embryos. J Assist Reprod Genet. 2013, 30 (3): 371-376. 10.1007/s10815-012-9928-2. Epub 2013 Jan 12PubMed CentralView ArticlePubMedGoogle Scholar
- Larman MG, Gardner DK: Vitrification of mouse embryos with super-cooled air. Fertil Steril. 2011, 95 (4): 1462-1466. 10.1016/j.fertnstert.2010.12.003. Epub 2010 Dec 31View ArticlePubMedGoogle Scholar
- Desai N, Goldfarb J: Examination of frozen cycles with replacement of a single thawed blastocyst. Reprod Biomed Online. 2005, 11: 349-354. 10.1016/S1472-6483(10)60843-7.View ArticlePubMedGoogle Scholar
- Desai N, Kinzer D, Loeb A, Goldfarb J: Use of Synthetic Serum Substitute and alpha-minimum essential medium for the extended culture of human embryos to the blastocyst stage. Hum Reprod. 1997, 12: 328-335. 10.1093/humrep/12.2.328.View ArticlePubMedGoogle Scholar
- Desai N, Blackmon H, Szeptycki J, Goldfarb J: Cryoloop vitrification of human day 3 cleavage-stage embryos: Post-vitrification development, pregnancy outcomes and live births. Reprod Biomed Online. 2007, 14: 208-213. 10.1016/S1472-6483(10)60789-4.View ArticlePubMedGoogle Scholar
- Seki S, Mazur P: The dominance of warming rate over cooling rate in the survival of mouse oocytes subjected to a vitrification procedure. Cryobiology. 2009, 59: 75-82. 10.1016/j.cryobiol.2009.04.012.PubMed CentralView ArticlePubMedGoogle Scholar
- Vanderzwalmen P, Zech N, Prapas Y, Panagiotidis Y, Papatheodorou A, Lejeune B, Jareno D, Vanderzwalmen S, Ectors F: Closed carrier device: a reality to vitrify oocytes and embryos in aseptic conditions. Gynecol Obstet Fertil. 2010, 38: 541-546. 10.1016/j.gyobfe.2010.07.011.View ArticlePubMedGoogle Scholar
- Desai N, Szeptycki J, Scott M, AbdelHafez F, Goldfarb J: Artificial Collapse of Blastocysts Before Vitrification: Mechanical vs. Laser Technique and Effect on Survival, Cell Number, and Cell Death in Early and Expanded Blastocysts. Biopreservation and Biobanking. 2008, 6: 181-190.Google Scholar
- Mukaida T, Oka C, Goto T, Takahashi K: Artificial shrinkage of blastocoeles using either a micro-needle or a laser pulse prior to the cooling steps of vitrification improves survival rate and pregnancy outcome of vitrified human blastocysts. Hum Reprod. 2006, 21: 3246-3252. 10.1093/humrep/del285.View ArticlePubMedGoogle Scholar
- Iwayama H, Hochi S, Yamashita M: In vitro and in vivo viability of human blastocysts collapsed by laser pulse or osmotic shock prior to vitrification. J Assist Reprod Genet. 2011, 28: 355-361. 10.1007/s10815-010-9522-4.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.